HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), the HER2 test positivity is defined by protein overexpression (score 3+) at im...

Full description

Bibliographic Details
Main Authors: Konstantinos Venetis, Edoardo Crimini, Elham Sajjadi, Chiara Corti, Elena Guerini-Rocco, Giuseppe Viale, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Molecular Biosciences
Subjects:
breast cancer
biomarkers
HER2 low expression
HER2 ultra low
targeted therapy
antibody-drug conjugate
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2022.834651/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2022.834651/full

Similar Items